CD40 and neoplasm: Agonistic CD40 monoclonal antibodies have been under active investigation as novel immunomodulatory agents that could potentially overcome tumor signals that weaken DCs, leading to enhanced antigen-dependent DC activity and a break in tumor immune tolerance.